{"id":21557,"date":"2026-11-10T10:31:05","date_gmt":"2026-11-10T10:31:05","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=webinar-and-podcast&p=21557"},"modified":"2026-11-10T11:00:57","modified_gmt":"2026-11-10T11:00:57","slug":"get-it-right-from-the-start-how-to-build-confidence-through-the-hit-discovery-process","status":"publish","type":"webinar-and-podcast","link":"https:\/\/www.sygnaturediscovery.com\/fr\/webinar-and-podcast\/get-it-right-from-the-start-how-to-build-confidence-through-the-hit-discovery-process\/","title":{"rendered":"Get it right from the start \u2013 How to build confidence through the hit discovery process."},"content":{"rendered":"\n

Integrating FIDA\u2122 and Biacore\u2122 SPR for optimal results<\/strong><\/h2>\n\n\n\n

Biophysical discovery depends on confidence in your reagents from the very beginning. When protein quality, stability, and behavior are fully understood early in a campaign, downstream hit identification and characterization become faster, more reliable, and far less prone to costly surprises.<\/p>\n\n\n\n

As drug discovery programs increasingly target challenging proteins, novel modalities, and complex biological systems, researchers need workflows that can generate robust data while reducing risk at every stage. But how can you confidently assess reagent quality, troubleshoot difficult assays, and ensure that promising hits are genuinely worth pursuing?<\/p>\n\n\n\n

In this webinar, experts from Sygnature Discovery, Fida Biosystems, and Cytiva<\/strong> explore how combining FIDA\u2122 (Flow Induced Dispersion Analysis)<\/strong> and Biacore\u2122 SPR<\/strong> creates a powerful hit discovery workflow that helps researchers build confidence from the start. Together, these complementary technologies provide insights into reagent quality, molecular interactions, and hit validation, enabling teams to make better decisions earlier in discovery programs.<\/p>\n\n\n\n

Drawing on real-world case studies, the discussion will showcase how integrated biophysical approaches can help overcome common challenges, unlock previously difficult targets, and generate the high-quality data needed to advance the most promising molecules.<\/p>\n\n\n\n

Watch the webinar now.<\/a><\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n

In This Webinar You’ll Learn<\/strong><\/h2>\n\n\n\n
\n
\n \n \n\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Start with Better Reagents<\/h3>\n\n\n\n

Why understanding protein quality, stability, and behaviour early can improve confidence throughout the discovery process.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n\n<\/svg>\n\n \n <\/section>\n\n\n
\n

De-Risk Challenging Targets<\/h3>\n\n\n\n

How integrated biophysical workflows can support difficult targets, including complex and membrane-associated proteins.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Understand Complex Sensorgrams<\/h3>\n\n\n\n

Approaches for investigating unexpected binding behaviour and gaining greater confidence in your data.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Generate More Reliable Hits<\/h3>\n\n\n\n

How combining solution-based and surface-based technologies can strengthen hit validation and prioritization.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n \n \n\n<\/svg>\n\n \n <\/section>\n\n\n
\n

Improve Decision-Making Earlier<\/h3>\n\n\n\n

Why reducing uncertainty at the start of a campaign can save valuable time and resources downstream.<\/p>\n\n\n\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

Key Discussion Topics<\/strong><\/h2>\n\n\n\n
    \n
  • The growing challenge of working with difficult targets and emerging therapeutic modalities<\/li>\n\n\n\n
  • The role of reagent assessment and quality control in successful hit discovery campaigns<\/li>\n\n\n\n
  • How FIDA\u2122 and Biacore\u2122 SPR provide complementary information within a single workflow<\/li>\n\n\n\n
  • Strategies for improving assay robustness and reducing false positives or misleading results<\/li>\n\n\n\n
  • Lessons learned from real-world discovery programmes and biophysical screening campaigns<\/li>\n\n\n\n
  • How integrated technology platforms can accelerate progression from screening to qualified hits<\/li>\n<\/ul>\n\n\n\n
    <\/div>\n\n\n\n

    Ready to Explore the Full Discussion?<\/strong> Watch it below.<\/strong><\/h1>\n\n\n
    \n \n \n\n
    \n